We are a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan diseases. We are initially focusing on SCD, a genetic disorder and a significant unmet medical need. Our lead product, Endari, is a pharmaceutical grade L-glutamine oral powder, treatment that demonstrated positive clinical results in our completed Phase 3 clinical trial for sickle cell anemia and sickle ß0
Company profile
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Afh Acquisition Iv, Inc., Emmaus Holdings, Inc., Emmaus Life Sciences, Inc.
SEC CIK
Corporate docs
Subsidiaries
Emmaus Medical, Inc. • Emmaus Medical Japan, Inc. • Newfield Nutrition Corp. • Emmaus Medical Europe, Ltd. • Emmaus Life Sciences, Co. Ltd • EJ Holdings, Inc. ...
Latest filings (excl ownership)
15-12G
Securities registration termination
22 Jul 19
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jul 19
8-K
MYnd Analytics and Emmaus Life Sciences Stockholders Approve Merger and Spin-off Transactions
11 Jul 19
8-K
Emmaus Life Sciences Announces Initiation of its Diverticulosis Study
8 Jul 19
DEFA14A
Additional proxy soliciting materials
8 Jul 19
8-K
Emmaus Life Sciences Announces Hiring of New Endari® Product Manager
3 Jul 19
DEFA14A
Additional proxy soliciting materials
3 Jul 19
8-K
Other Events
24 Jun 19
DEFA14A
Additional proxy soliciting materials
24 Jun 19
DEFM14A
Proxy related to merger
14 Jun 19
Latest ownership filings
SC 13D/A
EMI Holding, Inc.
1 Aug 19
4
Wei Peu ZEN
12 Jul 19
4
Yutaka Niihara
11 Jul 19
4
Joseph Charles Sherwood III
21 Jun 19
3
Joseph Charles Sherwood III
3 Jun 19
4
Yutaka Niihara
31 May 19
4
Change in insider ownership
7 Mar 19
SC 13D/A
Emmaus Life Sciences, Inc.
14 Jan 19
3/A
Wei Peu ZEN
21 Dec 18
4
Wei Peu ZEN
20 Dec 18
Financial summary
Quarter (USD) | Mar 19 | Dec 18 | Sep 18 | Jun 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 18 | Dec 17 | Dec 16 | Dec 15 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 15.31 mm | 15.31 mm | 15.31 mm | 15.31 mm | 15.31 mm | 15.31 mm |
Cash burn (monthly) | 590.00 k | (no burn) | 4.72 mm | 5.51 mm | 428.00 k | 526.75 k |
Cash used (since last report) | 37.12 mm | n/a | 296.79 mm | 346.49 mm | 26.93 mm | 33.14 mm |
Cash remaining | -21.81 mm | n/a | -281.48 mm | -331.18 mm | -11.62 mm | -17.83 mm |
Runway (months of cash) | -37.0 | n/a | -59.7 | -60.1 | -27.1 | -33.8 |